|
1
|
Oehler MK, Brand A and Wain GV: Molecular
genetics and endometrial cancer. J Br Menopause Soc. 9:27–31. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wunsche W, Tenniswood MP, Schneider MR and
Vollmer G: Estrogenic regulation of clusterin mRNA in normal and
malignant endometrial tissue. Int J Cancer. 76:684–688. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rosenberg ME and Silkensen J: Clusterin:
physiologic and pathophysiologic considerations. Int J Biochem Cell
Biol. 27:633–645. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shannan B, Seifert M, Leskov K, Willis J,
Boothman D, Tilgen W and Reichrath J: Challenge and promise: roles
for clusterin in pathogenesis, progression and therapy of cancer.
Cell Death Differ. 13:12–19. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Trougakos IP, Lourda M, Agiostratidou G,
Kletsas D and Gonos ES: Differential effects of
clusterin/apolipoprotein J on cellular growth and survival. Free
Radic Biol Med. 38:436–449. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Scaltriti M, Santamaria A, Paciucci R and
Bettuzzi S: Intracellular clusterin induces G2-M phase arrest and
cell death in PC-3 prostate cancer cells. Cancer Res. 64:6174–6182.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Scaltriti M, Bettuzzi S, Sharrard RM,
Caporali A, Caccamo AE and Maitland NJ: Clusterin overexpression in
both malignant and nonmalignant prostate epithelial cells induces
cell cycle arrest and apoptosis. Br J Cancer. 91:1842–1850. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Andersen CL, Schepeler T, Thorsen K, et
al: Clusterin expression in normal mucosa and colorectal cancer.
Mol Cell Proteomics. 6:1039–1048. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Redondo M, Villar E, Torres-Munoz J,
Tellez T, Morell M and Petito CK: Overexpression of clusterin in
human breast carcinoma. Am J Pathol. 157:393–399. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kurahashi T, Muramaki M, Yamanaka K, Hara
I and Miyake H: Expression of the secreted form of clusterin
protein in renal cell carcinoma as a predictor of disease
extension. BJU Int. 96:895–899. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pucci S, Bonanno E, Pichiorri F, Angeloni
C and Spagnoli LG: Modulation of different clusterin isoforms in
human colon tumorigenesis. Oncogene. 23:2298–2304. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
July LV, Beraldi E, So A, Fazli L, Evans
K, English JC and Gleave ME: Nucleotide-based therapies targeting
clusterin chemosensitize human lung adenocarcinoma cells both in
vitro and in vivo. Mol Cancer Ther. 3:223–232. 2004.PubMed/NCBI
|
|
13
|
Scaltriti M, Brausi M, Amorosi A, et al:
Clusterin (SGP-2, ApoJ) expression is downregulated in low- and
high-grade human prostate cancer. Int J Cancer. 108:23–30. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hassan MK, Watari H, Han Y, et al:
Clusterin is a potential molecular predictor for ovarian cancer
patient’s survival: targeting Clusterin improves response to
paclitaxel. J Exp Clin Cancer Res. 113:1–14. 2011.PubMed/NCBI
|
|
15
|
Watari H, Ohta Y, Hassan MK, Xiong Y,
Tanaka S and Sakuragi N: Clusterin expression predicts survival of
invasive cervical cancer patients treated with radical hysterectomy
and systematic lymphadenectomy. Gynecol Oncol. 108:527–532. 2008.
View Article : Google Scholar
|
|
16
|
Wellmann A, Thieblemont C, Pittaluga S,
Sakai A, Jaffe ES, Siebert P and Raffeld M: Detection of
differentially expressed genes in lymphomas using cDNA arrays:
identification of clusterin as a new diagnostic marker for
anaplastic large-cell lymphomas. Blood. 96:398–404. 2000.PubMed/NCBI
|
|
17
|
Moretti RM, Marelli MM, Mai S, Cariboni A,
Scaltriti M, Bettuzzi S and Limonta P: Clusterin isoforms
differentially affect growth and motility of prostate cells:
possible implications in prostate tumorigenesis. Cancer Res.
67:10325–10333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gleave M and Chi KN: Knock-down of the
cytoprotective gene, clusterin, to enhance hormone and
chemosensitivity in prostate and other cancers. Ann NY Acad Sci.
1058:1–15. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Seol MB, Bong JJ and Baik M: Expression
profiles of apoptosis genes in mammary epithelial cells. Mol Cells.
20:97–104. 2005.PubMed/NCBI
|
|
20
|
Miyake H, Hara I, Fujisawa M and Gleave
ME: The potential of clusterin inhibiting antisense
oligodeoxynucleotide therapy for prostate cancer. Expert Opin
Investig Drugs. 15:507–517. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ahn HJ, Bae J, Lee S, Ko JE, Yoon S, Kim
SJ and Sakuragi N: Differential expression of clusterin according
to histological type of endometrial carcinoma. Gynecol Oncol.
110:222–229. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Perlino E, Lovecchio M, Vacca RA, et al:
Regulation of mRNA and protein levels of beta1 integrin variants in
human prostate carcinoma. Am J Pathol. 157:1727–1734. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Moro L, Greco M, Ditonno P, Battaglia M,
Marra E and Perlino E: Transcriptional regulation of the β1C
integrin splice variant in human prostate adenocarcinoma. Int J
Oncol. 23:1601–1606. 2003.
|
|
24
|
Perlino E, Tommasi S, Moro L, Bellizzi A,
Marra E, Casavola V and Reshkin SJ: TGF-β1 and IGF-1 expression are
differently regulated by serum in metastatic and non-metastatic
human breast cancer cells. Int J Oncol. 16:155–160. 2000.
|
|
25
|
Maiorano E, Ciampolillo A, Viale G, et al:
Insulin-like growth factor 1 expression in thyroid tumors. Appl
Immunohistochem Mol Morphol. 8:110–119. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Perlino E, Moro L, Loverro G, Maiorano E,
Selvaggi L and Marra E: Role of the growth factors IGF-1 and
TGF-beta 1 in the endometrial adenocarcinoma. Int J Med Biol Env.
29:193–200. 2001.
|
|
27
|
Vacca RA, Marra E, Loverro G, et al:
Differential expression of beta 1c integrin messenger ribonucleic
acid and protein levels in human endometrium and decidua during the
menstrual cycle and pregnancy. J Clin Endocrinol Metab. 88:720–729.
2003. View Article : Google Scholar
|
|
28
|
Lovecchio M, Maiorano E, Vacca RA, et al:
Beta 1C integrin expression in human endometrial proliferative
diseases. Am J Pathol. 163:2543–2553. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tommasi S, Fedele V, Lacalamita R,
Crapolicchio A, Perlino E, Bellizzi A and Paradiso A: Molecular and
functional characteristics of erbB2 in normal and cancer breast
cells. Cancer Lett. 209:215–222. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vacca RA, Moro L, Maiorano E, Selvaggi L,
Marra E and Perlino E: Alternatively spliced variants of b1
integrin are involved in the modulation of human endometrial
transformation in different physiological/pathological conditions.
Recent Res Devel Proteins. 2:25–47. 2004.
|
|
31
|
Ciampolillo A, De Tullio C, Perlino E and
Maiorano E: The IGF-I axis in thyroid carcinoma. Curr Pharm Des.
13:729–735. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Moro L, Perlino E, Marra E, Languino LR
and Greco M: Regulation of beta1C and beta1A integrin expression in
prostate carcinoma cells. J Biol Chem. 279:1692–1702. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Moro L, Greco M, Maiorano E, Selvaggi L,
Marra E and Perlino E: Transcriptional regulation of β1 integrin
expression in the physio/pathological states of human endometrial
tissues. Int J Oncol. 26:457–465. 2005.
|
|
34
|
Fuzio P, Lucarelli G, Perlino E, Battaglia
M, Bettocchi C, Selvaggi FP and Ditonno P: Androgen deprivation
therapy regulation of β1C integrin expression in prostate cancer.
Oncol Rep. 22:327–335. 2009.
|
|
35
|
Fuzio P, Ditonno P, Lucarelli G, Battaglia
M, Trabucco S and Perlino E: Androgen deprivation therapy affects
BCL-2 expression in human prostate cancer. Int J Oncol.
39:1233–1242. 2011.PubMed/NCBI
|
|
36
|
Fuzio P, Ditonno P, Rutigliano M, et al:
Regulation of TGF-β1 expression by androgen deprivation therapy of
prostate cancer. Cancer Lett. 318:135–144. 2012.
|
|
37
|
Benedet JL, Bender H, Jones H, Ngan HY and
Pecorelli S: FIGO staging classifications and clinical practice
guidelines in the management of gynecologic cancers. FIGO Committee
on Gynecologic Oncology. Int J Gynaecol Obstet. 70:209–262. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bhatia P, Taylor WR, Greenberg AH and
Wright JA: Comparison of glyceraldehyde-3-phosphate dehydrogenase
and 28S-ribosomal RNA gene expression as RNA loading controls for
northern blot analysis of cell lines of varying malignant
potential. Anal Biochem. 216:223–226. 1994. View Article : Google Scholar
|
|
39
|
Peirson SN, Butler JN and Foster RG:
Experimental validation of novel and conventional approaches to
quantitative real-time PCR data analysis. Nucleic Acids Res.
31:e732003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rizzi F and Bettuzzi F: The clusterin
paradigm in prostate and breast carcinogenesis. Endocr Relat
Cancer. 17:R1–R17. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nieminen TT, Gylling A, Abdel-Rahman WM,
et al: Molecular analysis of endometrial tumorigenesis: importance
of complex hyperplasia regardless of atypia. Clin Cancer Res.
15:5772–5783. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Castrignanò T, D’Antonio M, Anselmo A, et
al: ASPicDB: a database resource for alternative splicing analysis.
Bioinformatics. 24:1300–1304. 2008.
|
|
43
|
Martelli PL, D’Antonio M, Bonizzoni P, et
al: ASPicDB: a database of annotated transcript and protein
variants generated by alternative splicing. Nucleic Acids Res.
39:D80–D85. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Riva A and Pesole G: A unique, consistent
identifier for alternatively spliced transcript variants. PLoS One.
4:e76312009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xie D, Lau SH, Sham JS, et al:
Up-regulated expression of cytoplasmic clusterin in human ovarian
carcinoma. Cancer. 103:277–283. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Brown TL, Moulton BC, Baker VV, Mira J and
Harmony JA: Expression of apolipoprotein J in the uterus is
associated with tissue remodeling. Biol Reprod. 52:1038–1049. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bettuzzi S, Scorcioni F, Astancolle S,
Davalli P, Scaltriti M and Corti A: Clusterin (SGP-2) transient
overexpression decreases proliferation rate of SV40-immortalized
human prostate epithelial cells by slowing down cell cycle
progression. Oncogene. 21:4328–4334. 2002. View Article : Google Scholar
|
|
48
|
Bettuzzi S, Astancolle S, Guidetti G,
Moretti M, Tiozzo R and Corti A: Clusterin (SGP-2) gene expression
is cell cycle dependent in normal human dermal fibroblasts. FEBS
Lett. 448:297–300. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Goldberg GS, Jin Z, Ichikawa H, Naito A,
Ohki M, El-Deiry WS and Tsuda H: Global effects of anchorage on
gene expression during mammary carcinoma cell growth reveal role of
tumor necrosis factor-related apoptosis-inducing ligand in anoikis.
Cancer Res. 61:1334–1337. 2001.
|
|
50
|
Caccamo AE, Desenzani S, Belloni L,
Borghetti AF and Bettuzzi S: Nuclear clusterin accumulation during
heat shock response: implications for cell survival and
thermotolerance induction in immortalized and prostate cancer
cells. J Cell Physiol. 207:208–219. 2006. View Article : Google Scholar
|
|
51
|
Frisch SM and Screaton RA: Anoikis
mechanisms. Curr Opin Cell Biol. 13:555–562. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Trougakos IP, Djeu JY, Gonos ES and
Boothman DA: Advances and challenges in basic and translational
research on clusterin. Cancer Res. 69:403–406. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yang CR, Leskov K, Hosley-Eberlein K,
Criswell T, Pink JJ, Kinsella TJ and Boothman DA: Nuclear
clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals
cell death. Proc Natl Acad Sci USA. 97:5907–5912. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Petropoulou C, Trougakos IP, Kolettas E,
Toussaint O and Gonos ES: Clusterin/apolipoprotein J is a novel
biomarker of cellular senescence that does not affect the
proliferative capacity of human diploid fibroblasto. FEBS Lett.
509:287–297. 2001. View Article : Google Scholar
|
|
55
|
Gonos ES, Derventzi A, Kveiborg M,
Agiostratidou G, Kassem M, Clark BF, Jat PS and Rattan SI: Cloning
and identification of genes that associate with mammalian
replicative senescence. Exp Cell Res. 240:66–74. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Miyake H, Hara I, Kamidono S, Gleave ME
and Eto H: Resistance to cytotoxic chemotherapy-induced apoptosis
in human prostate cancer cells is associated with intracellular
clusterin expression. Oncol Rep. 10:469–473. 2003.
|
|
57
|
Miyake H, Hara I, Gleave ME and Eto H:
Protection of androgen-dependent human prostate cancer cells from
oxidative stress-induced DNA damage by overexpression of clusterin
and its modulation by androgen. Prostate. 61:318–323. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zellweger T, Kiyama S, Chi K, Miyake H,
Adomat H, Skov K and Gleave ME: Overexpression of the
cytoprotective protein clusterin decreases radiosensitivity in the
human LNCaP prostate tumour model. BJU Int. 92:463–469. 2003.
View Article : Google Scholar : PubMed/NCBI
|
